GLP-1 Prescriptions Need Baseline Testing for Safety

The fastest GLP-1 prescription path skips the one thing that should actually guide dosing: a baseline. Online pharmacies can dispense semaglutide after a questionnaire. No fasting insulin, no HbA1c, no DEXA, no look at liver or kidney function. Just a form and a pen in the mail. Standard titration starts at a fixed dose and roughly doubles every four weeks over about 16 weeks. That schedule was designed around a population average. The person on the other end of it may be metabolically unwell and need a higher dose. Or they may be sensitive enough that the standard starting dose already overshoots appetite control into appetite suppression, and they start under-eating and dropping muscle with the fat, and then feel bad enough to quit. You cannot tell which one you're dealing with from a questionnaire. The signs of a dose that is too high are not always dramatic. Mood goes a little flat. Food loses all its appeal, not just junk food. Resting heart rate creeps up. HRV falls. Sleep gets worse. If nobody is measuring HRV and sleep between blood draws, you just hear "I stopped, it didn't agree with me." And the STEP 1 extension data shows what that costs. About two thirds of weight lost came back within a year of stopping, and cardiometabolic improvements drifted with it. A dropout is not just a bad experience. It is a lost outcome. The baseline labs are not complicated. Fasting insulin, HbA1c, CRP, lipids, liver and kidney function, thyroid, sex hormones, body composition by DEXA. Run them before you prescribe. Run them again during treatment. Labs can move before weight does. What actually takes time is figuring out the right dose for this person, and that only happens with data.